Does Pneumococcal Vaccination Have an Effect on Hospital Costs?

OBJECTIVE: It is known that inpatient hospital costs are much higher than outpatient services. It was aimed to investigate the effect of pneumococcal vaccination on hospitalizations. MATERIAL AND METHODS: The direct hospitalization costs, length of stay, and factors of the vaccinated and unvaccinated patients in the same hospital during the 12-month follow-up of the patients who received pneumococcal vaccine between November 15, 2018, and November 15, 2020, in 3 chest diseases and thoracic surgery training and research hospitals were analyzed by obtaining Hospital Information Management System records. Data were collected with Statistical Package for the Social Sciences version 23 program (IBM Corp.; Armonk, NY, USA) , and statistical evaluation was made. RESULTS: The mean age of 800 hospitalized patients, of whom 400 were unvaccinated and 400 were vaccinated, was 68.48 ± 11.97. There was no significant difference in the mean age of vaccinated and unvaccinated patients (P > .05). Five hundred sixty-six patients (70.8%) were aged 65 and over. Two hundred eighty (51.2%) of men were vaccinated and 120 (47.2%) of women were vaccinated, and there was no significant difference (P > .05). The mean hospital stay of these patients was 11.01 days, and those in the vaccinated group had an average mean hospital stay of 9.11 days and those in the unvaccinated group had a mean hospital stay less than 12.91 days (P < .001). Total 1-year hospitalization costs were $501.653.53 and the cost per person was calculated as $627.07. The cost per capita for the vaccinated group was $550.52, which was lower than the average cost of the unvaccinated group ($703.62) (P < .05). When comparing the status of being vaccinated, comorbidity, mortality, mean length of stay, chronic obstructive pulmonary disease, and heart disease were found to be statistically significant (P < .05). CONCLUSION: In our study, it was revealed that vaccination of patients hospitalized in chest disease hospitals with the pneumococcal vaccine reduced the average length of hospital stay by 41.7% and the cost of hospitalization by 27.8%.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Gibson GH, Loddenkemper R, Lundback B, Sibile Y. The Burden of Lung Disease. European Lung White Book. Eur Respir J. 2013:12-13.
2. Blasi F, Mantero M, Santus P, Tarsia P. Understanding the burden of pneumococcal disease in adults. Clin Microbiol Infect. 2012;18(suppl 5):7-14. [CrossRef]
3. Isturiz RE, Schmoele-Thoma B, Scott DA, et al. Pneumococ- Cal conjugate vaccine use in adults. Expert Rev Vaccines. 2016; 15(3):279-293. [CrossRef]
4. Ozlü T, Bülbül Y, Özsu S. Ulusal verilerle toplum kökenli pnömoniler. Tuberk Toraks Derg. 2007;55(2):191-212.
5. File TM. Streptococcus pneumoniae and community-acquired pneumonia: a cause for concern. Am J Med. 2004;117(3):39S- 50S. [CrossRef]
6. Wyrwich KW, Yu H, Sato R, Strutton D, Powers JH. Community- acquired pneumonia: symptoms and burden of illness at diagnosis among US adults aged 50 years and older. Patient. 2013;6(2):125-134. [CrossRef]
7. Sethi S, Murphy TF. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N Engl J Med. 2008; 359(22):2355-2365. [CrossRef]
8. Forum of International Respiratory Societies. The Global Impact of Respiratory Disease. 2nd edn. Sheffield: ERS; 2017.
9. Polsky D, Bonafede M, Suaya JA. Comorbidities as a driver of the excess costs of community-acquired pneumonia in U.S. commercially-insured working age adults. BMC Health Serv Res. 2012;12:379. [CrossRef]
10. Koşar F, Alıcı DE, Hacibedel B, Arpınar Yiğitbaş B, Golabi P, Çuhadaroğlu C. Burden of community-acquired pneumonia in adults over 18 y of age. Hum Vaccin Immunother. 2017;13(7): 1673-1680. [CrossRef]
11. Karadeniz G, Kılınç O. Ölmez A ve ark. Erişkin kronik akciğer hastalıklarında pnömokok infeksiyonu ve aşı ile korunma. Tuberk Toraks. 2020;68(3):305-320.
12. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJL. Measuring the global burden of disease and risk factors, 1990- 2001. In: Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJL, eds. Global Burden of Disease and Risk Factors. World Bank: Washington (DC):2006.
13. Brown PD. Adherence to guidelines for community-acquired pneumonia: does it decrease cost of care? Pharmacoeconomics. 2004;22(7):413-420. [CrossRef]
14. Polverino E, Torres Marti A. Community-acquired pneumonia. Minerva Anestesiol. 2011;77(2):196-211.
15. Grossman RF, Rotschafer JC, Tan JS. Antimicrobial treatment of lower respiratory tract infections in the hospital setting. Am J Med. 2005;118(suppl 7A):29S-38S. [CrossRef]
16. Bauer TT, Welte T, Ernen C, et al. Cost analyses of communityacquired pneumonia from the hospital perspective. Chest. 2005;128(4):2238-2246. [CrossRef]
17. Kobashi Y, Okimoto N, Matsushima T, Soejima R. Clinical analysis of community-acquired pneumonia in the elderly. Intern Med. 2001;40(8):703-707. [CrossRef]
18. Fine MJ, Stone RA, Lave JR, et al. Implementation of an evidence- based guideline to reduce duration of intravenous antibiotic therapy and length of stay for patients hospitalized with community-acquired pneumonia: a randomized controlled trial. Am J Med. 2003;115(5):343-351. [CrossRef]
19. Menéndez R, Ferrando D, Vallés JM, Martínez E, Perpiñá M. Initial risk class and length of hospital stay in communityacquired pneumonia. Eur Respir J. 2001;18(1):151-156. [CrossRef]
20. Neill AM, Martin IR, Weir R, et al. Community acquired pneumonia: aetiology and usefulness of severity criteria on admission. Thorax. 1996;51(10):1010-1016. [CrossRef]
21. Ortaköylü MG, Altın S, Bahadır A. Activity-based costing management and hospital cost in patients with chronic obstructive pulmonary disease. Eur J Gen Med. 2016;13(2):116-126. [CrossRef]
22. Andreassen SL, Liaaen ED, Stenfors N, Henriksen AH. Impact of pneumonia on hospitalizations due to acute exacerbations of COPD. Clin Respir J. 2014;8(1):93-99. [CrossRef]
23. Søgaard M, Madsen M, Løkke A, Hilberg O, Sørensen HT, Thomsen RW. Incidence and outcomes of patients hospitalized with COPD exacerbation with and without pneumonia. Int J Chron Obstruct Pulmon Dis. 2016;11:455-465. [CrossRef]
24. Restrepo MI, Mortensen EM, Pugh JA, Anzueto A. COPD is associated with increased mortality inpatients with community acquired pneumonia. Eur Respir J. 2006;28(2):346-351. [CrossRef]
25. Ipsos Healthcare. PneuVue. Adult pneumonia vaccine understanding in Europe. A new view into pneumonia among older adults. Available at: https ://ww w.ips os.co m/sit es/de fault /file s/ pub licat ion/1 970-0 1/ips os-he althc are-p neu-v ue- report.pdf. Erişim Tarihi: Mart 2020.
26. Andre FE, Booy R, Bock HL, et al. Vaccination greatly reduces disease, disability, death and inequity worldwide. Bull World Health Organ. 2008;86(2):140-146. [CrossRef]

APA	ŞİMŞEK N, Uslu O, Oruç Ö, ALTIN S, YALNIZ E, Karakurt Z, BOLAT E, Kul S, KILINC O, Sayiner A (2023). Does Pneumococcal Vaccination Have an Effect on Hospital Costs?. , 165 - 169. 10.5152/ThoracResPract.2023.22171
Chicago	ŞİMŞEK Nurdan,Uslu Ozgur,Oruç Özlem,ALTIN SEDAT,YALNIZ ENVER,Karakurt Zuhal,BOLAT ERKUT,Kul Seval,KILINC OGUZ,Sayiner Abdullah Does Pneumococcal Vaccination Have an Effect on Hospital Costs?. (2023): 165 - 169. 10.5152/ThoracResPract.2023.22171
MLA	ŞİMŞEK Nurdan,Uslu Ozgur,Oruç Özlem,ALTIN SEDAT,YALNIZ ENVER,Karakurt Zuhal,BOLAT ERKUT,Kul Seval,KILINC OGUZ,Sayiner Abdullah Does Pneumococcal Vaccination Have an Effect on Hospital Costs?. , 2023, ss.165 - 169. 10.5152/ThoracResPract.2023.22171
AMA	ŞİMŞEK N,Uslu O,Oruç Ö,ALTIN S,YALNIZ E,Karakurt Z,BOLAT E,Kul S,KILINC O,Sayiner A Does Pneumococcal Vaccination Have an Effect on Hospital Costs?. . 2023; 165 - 169. 10.5152/ThoracResPract.2023.22171
Vancouver	ŞİMŞEK N,Uslu O,Oruç Ö,ALTIN S,YALNIZ E,Karakurt Z,BOLAT E,Kul S,KILINC O,Sayiner A Does Pneumococcal Vaccination Have an Effect on Hospital Costs?. . 2023; 165 - 169. 10.5152/ThoracResPract.2023.22171
IEEE	ŞİMŞEK N,Uslu O,Oruç Ö,ALTIN S,YALNIZ E,Karakurt Z,BOLAT E,Kul S,KILINC O,Sayiner A "Does Pneumococcal Vaccination Have an Effect on Hospital Costs?." , ss.165 - 169, 2023. 10.5152/ThoracResPract.2023.22171
ISNAD	ŞİMŞEK, Nurdan vd. "Does Pneumococcal Vaccination Have an Effect on Hospital Costs?". (2023), 165-169. https://doi.org/10.5152/ThoracResPract.2023.22171

APA	ŞİMŞEK N, Uslu O, Oruç Ö, ALTIN S, YALNIZ E, Karakurt Z, BOLAT E, Kul S, KILINC O, Sayiner A (2023). Does Pneumococcal Vaccination Have an Effect on Hospital Costs?. Thoracic research and practice, 24(3), 165 - 169. 10.5152/ThoracResPract.2023.22171
Chicago	ŞİMŞEK Nurdan,Uslu Ozgur,Oruç Özlem,ALTIN SEDAT,YALNIZ ENVER,Karakurt Zuhal,BOLAT ERKUT,Kul Seval,KILINC OGUZ,Sayiner Abdullah Does Pneumococcal Vaccination Have an Effect on Hospital Costs?. Thoracic research and practice 24, no.3 (2023): 165 - 169. 10.5152/ThoracResPract.2023.22171
MLA	ŞİMŞEK Nurdan,Uslu Ozgur,Oruç Özlem,ALTIN SEDAT,YALNIZ ENVER,Karakurt Zuhal,BOLAT ERKUT,Kul Seval,KILINC OGUZ,Sayiner Abdullah Does Pneumococcal Vaccination Have an Effect on Hospital Costs?. Thoracic research and practice, vol.24, no.3, 2023, ss.165 - 169. 10.5152/ThoracResPract.2023.22171
AMA	ŞİMŞEK N,Uslu O,Oruç Ö,ALTIN S,YALNIZ E,Karakurt Z,BOLAT E,Kul S,KILINC O,Sayiner A Does Pneumococcal Vaccination Have an Effect on Hospital Costs?. Thoracic research and practice. 2023; 24(3): 165 - 169. 10.5152/ThoracResPract.2023.22171
Vancouver	ŞİMŞEK N,Uslu O,Oruç Ö,ALTIN S,YALNIZ E,Karakurt Z,BOLAT E,Kul S,KILINC O,Sayiner A Does Pneumococcal Vaccination Have an Effect on Hospital Costs?. Thoracic research and practice. 2023; 24(3): 165 - 169. 10.5152/ThoracResPract.2023.22171
IEEE	ŞİMŞEK N,Uslu O,Oruç Ö,ALTIN S,YALNIZ E,Karakurt Z,BOLAT E,Kul S,KILINC O,Sayiner A "Does Pneumococcal Vaccination Have an Effect on Hospital Costs?." Thoracic research and practice, 24, ss.165 - 169, 2023. 10.5152/ThoracResPract.2023.22171
ISNAD	ŞİMŞEK, Nurdan vd. "Does Pneumococcal Vaccination Have an Effect on Hospital Costs?". Thoracic research and practice 24/3 (2023), 165-169. https://doi.org/10.5152/ThoracResPract.2023.22171